Piramal Pharma reduced its net loss to ₹69.39 crore for Q1 FY27, supported by a 17.4% rise in revenue to ₹2,269.9 crore. The company reported an 82.9% jump in EBITDA, reflecting improved operational efficiency across its CDMO and healthcare divisions. Investors are now focused on whether the company can maintain these margin gains amid ongoing raw material costs.
Piramal Pharma Limited has announced a narrower net loss for the first quarter of the 2027 fiscal year, marking a positive shift in its operational performance. The consolidated net loss for the quarter reached ₹69.39 crore, showing improvement compared to the ₹81.7 crore loss reported in the same quarter last year. This change was largely supported by a revenue increase of 17.4%, reaching ₹2,269.9 crore.
Operational Growth Across Key Segments
The company’s operational profitability, measured by EBITDA, saw a significant boost of 82.9% to ₹195.2 crore, compared to ₹106.7 crore in the previous year's first quarter. This helped the EBITDA margin expand to 8.6%, up from 5.5% last year. Leadership attributed this performance to consistent growth in its three primary business areas: Contract Development and Manufacturing (CDMO), Hospital Generics, and Consumer Healthcare.
The CDMO business, which provides development and manufacturing services to other pharmaceutical companies, saw broad-based growth across both domestic and international facilities. Increased order inflows and steady request-for-proposal activity were key drivers for this segment. Meanwhile, the Complex Hospital Generics division continued to focus on its market presence, particularly in inhalation anesthesia, while progressing with the integration of the Kenalog business.
Consumer Healthcare and Strategic Margins
The Consumer Healthcare division reported strong momentum, driven largely by its 'Power Brands,' which grew 23% and accounted for over half of the segment's total sales. The company’s focus on e-commerce channels also paid off, with sales in this area rising 40% to represent 28% of the division's revenue. Additionally, the company launched a new brand, 'i-choose,' targeting the women’s intimate care market.
While the financial results show clear improvement, the company noted that it has used strategies like disciplined pricing and cost-optimization to manage the pressure of raw material inflation. These efforts have been vital in shielding profit margins from wider sector pressures. As of July 29, 2026, shares of Piramal Pharma closed at ₹195, up 0.81%. The next major monitorable for investors will be whether the company can sustain this margin expansion in subsequent quarters while navigating potential volatility in global drug manufacturing demand and the continued integration of recent acquisitions.